Sekundær profylakse til patienter med iskæmisk hjertesygdom i almen praksis

Research output: Contribution to journal › Journal article › peer-review

Standard

Sekundær profylakse til patienter med iskæmisk hjertesygdom i almen praksis. / Hamm, Lena R.V.; Bjerrum, Lars; Aarslev, Peter J.; Munck, Anders P.; Vach, Kirstin; Kragstrup, Jacob.

In: Ugeskrift for Laeger, Vol. 164, No. 27, 01.07.2002, p. 3534-3437.

Research output: Contribution to journal › Journal article › peer-review

Harvard

Hamm, LRV, Bjerrum, L, Aarslev, PJ, Munck, AP, Vach, K & Kragstrup, J 2002, 'Sekundær profylakse til patienter med iskæmisk hjertesygdom i almen praksis', Ugeskrift for Laeger, vol. 164, no. 27, pp. 3534-3437.

APA

Hamm, L. R. V., Bjerrum, L., Aarslev, P. J., Munck, A. P., Vach, K., & Kragstrup, J. (2002). Sekundær profylakse til patienter med iskæmisk hjertesygdom i almen praksis. Ugeskrift for Laeger, 164(27), 3534-3437.

Vancouver

Hamm LRV, Bjerrum L, Aarslev PJ, Munck AP, Vach K, Kragstrup J. Sekundær profylakse til patienter med iskæmisk hjertesygdom i almen praksis. Ugeskrift for Laeger. 2002 Jul 1;164(27):3534-3437.

Author

Hamm, Lena R.V. ; Bjerrum, Lars ; Aarslev, Peter J. ; Munck, Anders P. ; Vach, Kirstin ; Kragstrup, Jacob. / Sekundær profylakse til patienter med iskæmisk hjertesygdom i almen praksis. In: Ugeskrift for Laeger. 2002 ; Vol. 164, No. 27. pp. 3534-3437.

Bibtex

@article{72b3bdf24e8043c0b95bb247a9fdabfe,
title = "Sekund{\ae}r profylakse til patienter med isk{\ae}misk hjertesygdom i almen praksis",
abstract = "Introduction: We examined the extent to which the Danish College of General Practitioners' guidelines of 1998, {"}Prevention of ischaemic heart disease in general practice - with special focus on dyslipidaemia{"}, are complied with in the secondary preventive care of patients with ischaemic heart disease. Material and Method: Twenty-six general practitioners from Ringkj{\o}bing Country registered all patients with ischaemic heart disease consecutively over three weeks in May 1999. One hundred and ten patients had suffered acute myocardial infarction, 141 had ischaemic heart disease without acute myocardial infarction. Blood pressure, total cholesterol, and use of cardiovascular drugs were registered. Results: In patients with previous acute myocardial infarction, 66% had had their serum cholesterol measured within the past year, 76% were being treated with acetylsalicylic acid, 46% with beta-blockers, and 27% with lipid-lowering drugs. Of the patients with previous myocardial infarction and a serum cholesterol level ≥5.0 mmol/l, 33% took lipid-lowering drugs. Discussion: The present study demonstrates that in some areas actual treatment practice does not always comply with the given recommendations. In particular the frequency of cholesterol measuring and treatment with beta-blockers and lipid-lowering drugs show that continued, targeted quality development is required.",
author = "Hamm, {Lena R.V.} and Lars Bjerrum and Aarslev, {Peter J.} and Munck, {Anders P.} and Kirstin Vach and Jacob Kragstrup",
year = "2002",
month = jul,
day = "1",
language = "Dansk",
volume = "164",
pages = "3534--3437",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "27",

}

RIS

TY - JOUR

T1 - Sekundær profylakse til patienter med iskæmisk hjertesygdom i almen praksis

AU - Hamm, Lena R.V.

AU - Bjerrum, Lars

AU - Aarslev, Peter J.

AU - Munck, Anders P.

AU - Vach, Kirstin

AU - Kragstrup, Jacob

PY - 2002/7/1

Y1 - 2002/7/1

N2 - Introduction: We examined the extent to which the Danish College of General Practitioners' guidelines of 1998, "Prevention of ischaemic heart disease in general practice - with special focus on dyslipidaemia", are complied with in the secondary preventive care of patients with ischaemic heart disease. Material and Method: Twenty-six general practitioners from Ringkjøbing Country registered all patients with ischaemic heart disease consecutively over three weeks in May 1999. One hundred and ten patients had suffered acute myocardial infarction, 141 had ischaemic heart disease without acute myocardial infarction. Blood pressure, total cholesterol, and use of cardiovascular drugs were registered. Results: In patients with previous acute myocardial infarction, 66% had had their serum cholesterol measured within the past year, 76% were being treated with acetylsalicylic acid, 46% with beta-blockers, and 27% with lipid-lowering drugs. Of the patients with previous myocardial infarction and a serum cholesterol level ≥5.0 mmol/l, 33% took lipid-lowering drugs. Discussion: The present study demonstrates that in some areas actual treatment practice does not always comply with the given recommendations. In particular the frequency of cholesterol measuring and treatment with beta-blockers and lipid-lowering drugs show that continued, targeted quality development is required.

AB - Introduction: We examined the extent to which the Danish College of General Practitioners' guidelines of 1998, "Prevention of ischaemic heart disease in general practice - with special focus on dyslipidaemia", are complied with in the secondary preventive care of patients with ischaemic heart disease. Material and Method: Twenty-six general practitioners from Ringkjøbing Country registered all patients with ischaemic heart disease consecutively over three weeks in May 1999. One hundred and ten patients had suffered acute myocardial infarction, 141 had ischaemic heart disease without acute myocardial infarction. Blood pressure, total cholesterol, and use of cardiovascular drugs were registered. Results: In patients with previous acute myocardial infarction, 66% had had their serum cholesterol measured within the past year, 76% were being treated with acetylsalicylic acid, 46% with beta-blockers, and 27% with lipid-lowering drugs. Of the patients with previous myocardial infarction and a serum cholesterol level ≥5.0 mmol/l, 33% took lipid-lowering drugs. Discussion: The present study demonstrates that in some areas actual treatment practice does not always comply with the given recommendations. In particular the frequency of cholesterol measuring and treatment with beta-blockers and lipid-lowering drugs show that continued, targeted quality development is required.

UR - http://www.scopus.com/inward/record.url?scp=2242469127&partnerID=8YFLogxK

M3 - Tidsskriftartikel

C2 - 12116682

AN - SCOPUS:2242469127

VL - 164

SP - 3534

EP - 3437

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 27

ER -

ID: 201128667